L Eugene Arnold1, Andrea S Young2, Martha A Belury1,3, Rachel M Cole1,2, Barbara Gracious1,4, Adina M Seidenfeld5, Hannah Wolfson1, Mary A Fristad1. 1. 1 Department of Psychiatry and Behavioral Health, The Ohio State University , Columbus, Ohio. 2. 2 Department of Psychiatry, Johns Hopkins University , Baltimore, Maryland. 3. 3 Department of Human Sciences, The Ohio State University , Columbus, Ohio. 4. 4 Nationwide Children's Hospital , Columbus, Ohio. 5. 5 Department of Psychological and Brain Sciences, University of Delaware , Newark, Delaware.
Abstract
OBJECTIVE: To examine fatty acid profiles, their response to omega-3 fatty acid (Ω3) supplementation, and associations with clinical status and treatment response in youth with mood disorders. METHODS: In a placebo-controlled 2X2 design, 7-14 year-olds (N = 95) in parallel pilot trials (depression N = 72; bipolar N = 23) were randomly assigned to 12 weeks of Ω3 supplementation (1.4 g eicosapentaenoic acid [EPA], 0.2 g docosahexaenoic acid [DHA], and 0.27 g other Ω3 per day); psychoeducational psychotherapy (PEP); their combination; or placebo (mainly oleic and linoleic acid) alone. Blood was drawn at baseline (N = 90) and endpoint (n = 65). Fatty acid levels were expressed as percent of total plasma fatty acids. Correlational and moderator/mediator analyses were done with SPSS Statistics 23. RESULTS: At baseline: (1) DHA correlated negatively with alpha-linolenic acid (ALA) (r = -0.23, p = 0.029); (2) Arachidonic acid (AA, Ω6) correlated negatively with global functioning (r = -0.24, p = 0.022); (3) Total Ω3 correlated negatively with age (r = -0.22, p = 0.036) and diastolic blood pressure (r = -0.31, p = 0.006). Moderation: Baseline ALA moderated response to Ω3 supplementation: ALA levels above the sample mean (lower DHA) predicted significantly better placebo-controlled response (p = 0.04). Supplementation effects: Compared to placebo, 2 g Ω3 per day increased EPA blood levels sevenfold and DHA levels by half (both p < 0.001). Body weight correlated inversely with increased EPA (r = -0.52, p = 0.004) and DHA (r = -0.54, p = 0.003) and positively with clinical mood response. Mediation: EPA increase baseline-to-endpoint mediated placebo-controlled global function and depression improvement: the greater the EPA increase, the less the placebo-controlled Ω3 improvement. CONCLUSION:Ω3 supplementation at 2 g/day increases blood levels substantially, more so in smaller children. A possible U-shaped response curve should be explored.
RCT Entities:
OBJECTIVE: To examine fatty acid profiles, their response to omega-3 fatty acid (Ω3) supplementation, and associations with clinical status and treatment response in youth with mood disorders. METHODS: In a placebo-controlled 2X2 design, 7-14 year-olds (N = 95) in parallel pilot trials (depression N = 72; bipolar N = 23) were randomly assigned to 12 weeks of Ω3 supplementation (1.4 g eicosapentaenoic acid [EPA], 0.2 g docosahexaenoic acid [DHA], and 0.27 g other Ω3 per day); psychoeducational psychotherapy (PEP); their combination; or placebo (mainly oleic and linoleic acid) alone. Blood was drawn at baseline (N = 90) and endpoint (n = 65). Fatty acid levels were expressed as percent of total plasma fatty acids. Correlational and moderator/mediator analyses were done with SPSS Statistics 23. RESULTS: At baseline: (1) DHA correlated negatively with alpha-linolenic acid (ALA) (r = -0.23, p = 0.029); (2) Arachidonic acid (AA, Ω6) correlated negatively with global functioning (r = -0.24, p = 0.022); (3) Total Ω3 correlated negatively with age (r = -0.22, p = 0.036) and diastolic blood pressure (r = -0.31, p = 0.006). Moderation: Baseline ALA moderated response to Ω3 supplementation: ALA levels above the sample mean (lower DHA) predicted significantly better placebo-controlled response (p = 0.04). Supplementation effects: Compared to placebo, 2 g Ω3 per day increased EPA blood levels sevenfold and DHA levels by half (both p < 0.001). Body weight correlated inversely with increased EPA (r = -0.52, p = 0.004) and DHA (r = -0.54, p = 0.003) and positively with clinical mood response. Mediation: EPA increase baseline-to-endpoint mediated placebo-controlled global function and depression improvement: the greater the EPA increase, the less the placebo-controlled Ω3 improvement. CONCLUSION: Ω3 supplementation at 2 g/day increases blood levels substantially, more so in smaller children. A possible U-shaped response curve should be explored.
Authors: Mary A Fristad; Anthony T Vesco; Andrea S Young; K Zachary Healy; Elias S Nader; William Gardner; Adina M Seidenfeld; Hannah L Wolfson; L Eugene Arnold Journal: J Clin Child Adolesc Psychol Date: 2016-11-07
Authors: Christine Henriksen; Kristin Haugholt; Magnus Lindgren; Anne Karin Aurvåg; Arild Rønnestad; Morten Grønn; Rønnaug Solberg; Atle Moen; Britt Nakstad; Rolf Kristian Berge; Lars Smith; Per Ole Iversen; Christian André Drevon Journal: Pediatrics Date: 2008-06 Impact factor: 7.124
Authors: Sarah A Keim; Abigail Jude; Katie Smith; Aiman Q Khan; Daniel L Coury; Joseph Rausch; Shivika Udaipuria; Megan Norris; Lindsay R Bartram; Anita R Narayanan; Lynette K Rogers Journal: J Autism Dev Disord Date: 2022-01-11
Authors: Noura M Darwish; Mohamed M A Elshaer; Saeedah Musaed Almutairi; Tse-Wei Chen; Mohamed Othman Mohamed; Wael B A Ghaly; Rabab Ahmed Rasheed Journal: Molecules Date: 2022-05-09 Impact factor: 4.927
Authors: Maximus Berger; Barnaby Nelson; Connie Markulev; Hok Pan Yuen; Miriam R Schäfer; Nilufar Mossaheb; Monika Schlögelhofer; Stefan Smesny; Ian B Hickie; Gregor E Berger; Eric Y H Chen; Lieuwe de Haan; Dorien H Nieman; Merete Nordentoft; Anita Riecher-Rössler; Swapna Verma; Andrew Thompson; Alison Ruth Yung; Patrick D McGorry; G Paul Amminger Journal: Front Psychiatry Date: 2019-06-06 Impact factor: 4.157
Authors: Cristina Menni; Jonas Zierer; Tess Pallister; Matthew A Jackson; Tao Long; Robert P Mohney; Claire J Steves; Tim D Spector; Ana M Valdes Journal: Sci Rep Date: 2017-09-11 Impact factor: 4.379
Authors: Robert M Post; Benjamin I Goldstein; Boris Birmaher; Robert L Findling; Benicio N Frey; Melissa P DelBello; David J Miklowitz Journal: J Affect Disord Date: 2020-03-06 Impact factor: 4.839